C4 Therapeutics, Inc. Stock Price, News & Analysis

C4 Therapeutics (Nasdaq: CCCC) announced an inducement grant of non-qualified stock options to one new employee approved by the independent directors on the Organization, Leadership and Compensation Committee.

The grant covers 85,480 shares, was made on January 26, 2026, and has an exercise price equal to the closing price of C4T common stock on the grant date. The options vest over four years: 25% on the first-year anniversary of the employee's start date and the remainder in 36 equal monthly installments, subject to continued employment.

C4 Therapeutics (Nasdaq: CCCC) outlined milestones through 2028 focused on advancing cemsidomide as an IKZF1/3 degrader and progressing internal discovery in inflammation and neuro‑degeneration. Key near‑term actions include initiating the Phase 2 MOMENTUM trial in Q1 2026 (recommended Phase 2 dose: 100 µg) with planned 12‑month enrollment, and initiating a Phase 1b combo trial with elranatamab in Q2 2026. Reported Phase 1 ORR was 40% at 75 µg and 53% at 100 µg. The company says cash runway extends to end of 2028, target NDA submission for fourth‑line cemsidomide by year‑end 2028, and up to three INDs for discovery programs by year‑end 2028.

C4 Therapeutics (Nasdaq: CCCC) management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference in Coral Gables, Florida, on December 3, 2025 at 3:25 pm ET. A live webcast of the presentation will be available on the company’s Investors website and an archived replay will be accessible for approximately 90 days after the event.

This presentation provides an opportunity for investors to hear management discuss clinical programs and corporate strategy.

C4 Therapeutics (Nasdaq: CCCC) reported Q3 2025 results and program updates on November 6, 2025. Key highlights include a completed equity offering that raised $125 million in gross proceeds (with potential for an additional $225 million if outstanding warrants are exercised), which the company says extends its runway to end of 2028. Clinically, cemsidomide showed a 53% overall response rate (ORR) at the 100 µg dose and 40% ORR at 75 µg in a Phase 1 multiple myeloma trial, with a median duration of response of 9.3 months. C4T entered a collaboration with Pfizer to test cemsidomide plus elranatamab and plans a Phase 2 MOMENTUM trial in Q1 2026 and a Phase 1b combination trial in Q2 2026. Financially, Q3 revenue was $11.2 million, net loss was $32.2 million, and cash and marketable securities were $199.8 million as of September 30, 2025 (excluding the October 2025 $125 million gross proceeds).

C4 Therapeutics (Nasdaq: CCCC) priced an underwritten offering on Oct 16, 2025 expected to provide $125.0 million in upfront gross proceeds.

The offering sells 21,895,000 shares and, in lieu of shares to certain investors, up to 28,713,500 pre-funded warrants. Each share or pre-funded warrant is issued with a Class A and Class B warrant exercisable at $2.22. Combined prices: $2.47 per share package and $2.4699 per pre-funded warrant package.

If all warrants are exercised, aggregate gross proceeds could reach $349.7 million. Closing is expected on or about Oct 17, 2025. Net proceeds will fund ongoing and planned clinical trials of cemsidomide including a registrational Phase 2 with dexamethasone and a Phase 1b with elranatamab, plus R&D and working capital.

C4 Therapeutics (NASDAQ:CCCC) has entered into a clinical trial collaboration and supply agreement with Pfizer to evaluate the combination of cemsidomide and elranatamab for treating relapsed/refractory multiple myeloma. The upcoming Phase 1b trial, set to begin in Q2 2026, will assess the safety and optimal dosing of cemsidomide (an IKZF1/3 degrader) with dexamethasone and elranatamab (Pfizer's BCMAxCD3 bispecific antibody) as a second-line or later therapy.

Under the agreement, Pfizer will provide elranatamab at no cost, while C4T will sponsor and conduct the trial. Early Phase 1 data shows cemsidomide demonstrates robust T-cell activation and cytokine expression, suggesting potential synergistic effects when combined with elranatamab to enhance anti-myeloma immune response.

C4 Therapeutics (NASDAQ:CCCC) presented promising Phase 1 clinical trial data for cemsidomide, an oral IKZF1/3 degrader, in combination with dexamethasone for treating relapsed/refractory multiple myeloma. The trial showed 50% overall response rate (ORR) at the highest dose level (100 µg) and 40% ORR at the 75 µg dose level in heavily pre-treated patients.

Key highlights include a median duration of response of 9.3 months across all dose levels, with median duration not yet reached at the two highest doses. The drug demonstrated a favorable safety profile with no treatment discontinuations and minimal dose reductions. The study involved 72 patients who had received a median of seven prior therapies, with 75% having previous BCMA-targeted therapy exposure.

C4T plans to pursue two distinct opportunities for accelerated approval through a Phase 2 trial in Q1 2026 for fourth-line therapy and a Phase 1b trial in Q2 2026 to evaluate combination with BCMA BiTE in second-line therapy.

C4 Therapeutics (NASDAQ: CCCC) announced that its collaboration partner Biogen received FDA acceptance of the IND application for BIIB142, an IRAK4 degrader targeting autoimmune diseases. This marks a significant milestone in their strategic collaboration initiated in 2018.

The partnership combines C4T's expertise in targeted protein degradation with Biogen's drug development capabilities. C4T has delivered two development candidates to Biogen, who will handle future clinical development and commercialization. C4T will receive a $2 million milestone payment when Biogen begins dosing patients in the BIIB142 clinical trial.

C4 Therapeutics (Nasdaq: CCCC) announced upcoming data presentation from its Phase 1 trial of cemsidomide in multiple myeloma at the International Myeloma Society Annual Meeting on September 20, 2025. The company has completed enrollment and dose escalation for the trial, which combines cemsidomide with dexamethasone.

The presentation will feature data from all safety and efficacy evaluable multiple myeloma patients across all dose levels. Initial results indicate a well-tolerated safety profile and compelling response rates. Dr. Binod Dhakal from the Medical College of Wisconsin will present the findings at 11:10 am ET in Toronto. C4T will host an investor webcast at 3 pm ET the same day to discuss the data and outline future clinical development plans.